Sanofi calls rejection of potential MS blockbuster 'unexpected'

Sanofi said the FDA’s recent rejection of its potential blockbuster MS treatment was “unexpected” and that the agency raised questions too late to make changes. The company "observed evolving perspectives within the FDA review team ...